Active Ingredient History

  • Now
Pruvanserin is a selective 5-HT2A receptor antagonist which was under development by Eli Lilly and Company for the treatment of insomnia. It was in phase II clinical trials in 2008 but appears to have been discontinued as it is no longer in the company's development pipeline. In addition to its sleep-improving properties, pruvanserin has also been shown to have antidepressant, anxiolytic, and working memory-enhancing effects in animal studies.   Wikipedia

  • SMILES: Fc1ccc(CCN2CCN(CC2)C(=O)c3cccc4c(c[nH]c34)C#N)cc1
  • Mol. Mass: 376.44
  • ALogP: 3.18
  • ChEMBL Molecule:
More Chemistry
emd-281014 | emd-390920 | lsn-2422347 | ly2422347 | ly-2422347 | pruvanserin


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue